Recurrence of Clostridium Difficile and Cytomegalovirus Infections in Patients with Ulcerative Colitis Who Undergo Ileal Pouch-Anal Anastomosis.


Journal

Digestive diseases and sciences
ISSN: 1573-2568
Titre abrégé: Dig Dis Sci
Pays: United States
ID NLM: 7902782

Informations de publication

Date de publication:
12 2021
Historique:
accepted: 04 12 2020
pubmed: 13 1 2021
medline: 15 12 2021
entrez: 12 1 2021
Statut: ppublish

Résumé

Patients with ulcerative colitis (UC) are at increased risk for infections such as Clostridium difficile and cytomegalovirus (CMV) colitis due to chronic immunosuppression. These patients often undergo multiple surgeries putting them at risk for recurrence of the infection. However, rates of recurrence in this setting and outcomes are not well understood. The aim of this study is to determine rates of recurrence of C difficile and CMV infection in patients undergoing multistage UC surgeries and effects of antibiotic prophylaxis on outcomes. All patients with UC who underwent IPAA between 2001 and 2017 (at two tertiary referral centers were identified. History of C. difficile or CMV colitis prior to any surgery and recurrence after IPAA was noted RESULTS: A total of 633 patients with UC who underwent IPAA were identified, of whom 8.1% patients had C. difficile and 2.7% had CMV infections. 9.8% of C. difficile and 5.9% of CMV patients recurred after IPAA. Rates of abdominal sepsis (14.7% vs. 12.7%), 90-day mortality (0% vs. 0.4%), pouchitis (36.8% vs. 45.0%), or return to stoma (7.4% vs. 5.4%) were similar between patients who did or did not have infections. In patients with C. difficile infection prior to first surgery, none of the patients who received prophylaxis had recurrent infection. Rates of C. difficile and CMV infections remain high in patients undergoing surgery for UC, with substantial minority developing recurrent infection during subsequent surgical procedures. Antibiotic prophylaxis in patients with a history of C difficile may reduce the rate of recurrent infection.

Sections du résumé

BACKGROUND
Patients with ulcerative colitis (UC) are at increased risk for infections such as Clostridium difficile and cytomegalovirus (CMV) colitis due to chronic immunosuppression. These patients often undergo multiple surgeries putting them at risk for recurrence of the infection. However, rates of recurrence in this setting and outcomes are not well understood.
AIM
The aim of this study is to determine rates of recurrence of C difficile and CMV infection in patients undergoing multistage UC surgeries and effects of antibiotic prophylaxis on outcomes.
METHODS
All patients with UC who underwent IPAA between 2001 and 2017 (at two tertiary referral centers were identified. History of C. difficile or CMV colitis prior to any surgery and recurrence after IPAA was noted RESULTS: A total of 633 patients with UC who underwent IPAA were identified, of whom 8.1% patients had C. difficile and 2.7% had CMV infections. 9.8% of C. difficile and 5.9% of CMV patients recurred after IPAA. Rates of abdominal sepsis (14.7% vs. 12.7%), 90-day mortality (0% vs. 0.4%), pouchitis (36.8% vs. 45.0%), or return to stoma (7.4% vs. 5.4%) were similar between patients who did or did not have infections. In patients with C. difficile infection prior to first surgery, none of the patients who received prophylaxis had recurrent infection.
CONCLUSIONS
Rates of C. difficile and CMV infections remain high in patients undergoing surgery for UC, with substantial minority developing recurrent infection during subsequent surgical procedures. Antibiotic prophylaxis in patients with a history of C difficile may reduce the rate of recurrent infection.

Identifiants

pubmed: 33433814
doi: 10.1007/s10620-020-06772-8
pii: 10.1007/s10620-020-06772-8
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4441-4447

Informations de copyright

© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature.

Références

Danese S, Fiorino G, Peyrin-Biroulet L et al. Biological agents for moderately to severely active ulcerative colitis a systematic review and network meta-analysis. Ann Intern Med. 2014;160:704–711
doi: 10.7326/M13-2403
Molodecky NA, Soon IS, Rabi DM et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:4–54
doi: 10.1053/j.gastro.2011.10.001
Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015;12:720–727
doi: 10.1038/nrgastro.2015.150
Peyrin-Biroulet L, Germain A, Patel AS, Lindsay JO. Systematic review: outcomes and post-operative complications following colectomy for ulcerative colitis. Aliment Pharmacol Ther. 2016;44:807–816
doi: 10.1111/apt.13763
de Silva S, Ma C, Proulx MC et al. Postoperative complications and mortality following colectomy for ulcerative colitis. Clin Gastroenterol Hepatol. 2011;9:972–980
doi: 10.1016/j.cgh.2011.07.016
Germain A, de Buck van Overstraeten A, Wolthuis A et al. Outcome of restorative proctocolectomy with an ileo-anal pouch for ulcerative colitis: effect of changes in clinical practice. Colorectal Dis. 2018;20:O30–O38
doi: 10.1111/codi.13948
Zittan E, Ma GW, Wong-Chong N et al. Ileal pouch-anal anastomosis for ulcerative colitis: a Canadian institution’s experience. Int J Colorectal Dis. 2017;32:281–285
doi: 10.1007/s00384-016-2670-y
Negron ME, Barkema HW, Rioux K et al. Clostridium difficile infection worsens the prognosis of ulcerative colitis. J Gastroenterol Hepatol 2014;28:373–380
Negron ME, Rezaie A, Barkema HW et al. Ulcerative colitis patients with clostridium difficile are at increased risk of death, colectomy, and postoperative complications: a population-based inception cohort study. Am J Gastroenterol. 2016;111:691–704
doi: 10.1038/ajg.2016.106
Skowron KB, Lapin B, Rubin M et al. Clostridium difficile infection in ulcerative colitis: Can alteration of the gut-associated microbiome contribute to pouch failure? Inflamm Bowel Dis. 2016;22:902–911
doi: 10.1097/MIB.0000000000000710
Kaplan GG, Hubbard J, Panaccione R et al. Risk of comorbidities on postoperative outcomes in patients with inflammatory bowel disease. Arch Surg. 2011;146:959–964
doi: 10.1001/archsurg.2011.194
Zhang T, Lin QY, Fei JX et al. Clostridium difficile infection worsen outcome of hospitalized patients with inflammatory bowel disease. Sci Rep. 2016;6:29791
doi: 10.1038/srep29791
Pillet S, Pozzetto B, Roblin X. Cytomegalovirus and ulcerative colitis: place of antiviral therapy. World J Gastroenterol. 2016;22:2030–2045
doi: 10.3748/wjg.v22.i6.2030
Park SC, Jeen YM, Jeen YT. Approach to cytomegalovirus infections in patients with ulcerative colitis. Korean J Intern Med. 2017;32:383–392
doi: 10.3904/kjim.2017.087
St-Louis E, Iqbal S, Feldman LS et al. Using the age-adjusted Charlson comorbidity index to predict outcomes in emergency general surgery. J Trauma Acute Care Surg. 2015;78:318–323
doi: 10.1097/TA.0000000000000457
Livingston EH, Passaro EP. Postoperative ileus. Dig Dis Sci. 1990;35:121–132. https://doi.org/10.1007/BF01537233 .
doi: 10.1007/BF01537233 pubmed: 2403907
Fazio VW, Tekkis PP, Remzi F et al. Quantification of risk for pouch failure after ileal pouch anal anastomosis surgery. Ann Surg. 2003;238:605–614 (discussion 614–607).
doi: 10.1097/01.sla.0000090940.39838.6a
Sheriff MZ, Mansoor E, Luther J et al. Opportunistic infections are more prevalent in crohn’s disease and ulcerative colitis: a large population-based study. Inflamm Bowel Dis. 2019;26:291–300
doi: 10.1093/ibd/izz147
Oh SJ, Lee CK, Kim YW et al. True cytomegalovirus colitis is a poor prognostic indicator in patients with ulcerative colitis flares: the 10-year experience of an academic referral inflammatory bowel disease center. Scand J Gastroenterol. 2019;54:976–983
doi: 10.1080/00365521.2019.1646798
Chen X, Deng J, Chen X, Wan S, Wang Y, Cao Q. High incidence and morbidity of clostridium difficile infection among hospitalized patients with inflammatory bowel disease—a prospective observational cohort study. J Dig Dis. 2019;20:460–466
doi: 10.1111/1751-2980.12798
Kistangari G, Lopez R, Shen B. Frequency and risk factors of clostridium difficile infection in hospitalized patients with pouchitis: a population-based study. Inflamm Bowel Dis. 2017;23:661–671
doi: 10.1097/MIB.0000000000001057
Negrón ME, Rezaie A, Barkema HW et al. Ulcerative colitis patients with clostridium difficile are at increased risk of death, colectomy, and postoperative complications: a population-based inception cohort study. Am. J. Gastroenterol. 2016;111:691–704
doi: 10.1038/ajg.2016.106
Lightner AL, Tse CS, Quinn K et al. Preoperative clostridium difficile infection does not affect pouch outcomes in patients with ulcerative colitis who undergo ileal pouch-anal anastomosis. Inflamm Bowel Dis. 2017;23:1195–1201
doi: 10.1097/MIB.0000000000001122
McDonald LC, Gerding DN, Johnson S et al. Clinical practice guidelines for clostridium difficile infection in adults and children: 2017 update by the infectious diseases society of America (IDSA) and society for healthcare epidemiology of America (SHEA). Clin Infect Dis. 2018;66:987–994
doi: 10.1093/cid/ciy149

Auteurs

Jonathan Pastrana Del Valle (JP)

Department of Surgery, Beth Israel Deaconess Medical Center, Beth Israel Deaconess Medical Center Suite 9B, 110 Francis Street, Boston, MA, 02215, USA.
Harvard Medical School, Boston, MA, USA.

Grace C Lee (GC)

Division of Gastrointestinal and Oncologic Surgery, Massachusetts General Hospital, 55 Fruit St, Boston, MA, 02114, USA.
Harvard Medical School, Boston, MA, USA.

Jose Cataneo Serrato (JC)

Department of Surgery, Beth Israel Deaconess Medical Center, Beth Israel Deaconess Medical Center Suite 9B, 110 Francis Street, Boston, MA, 02215, USA.
Division of Gastrointestinal and Oncologic Surgery, Massachusetts General Hospital, 55 Fruit St, Boston, MA, 02114, USA.
Harvard Medical School, Boston, MA, USA.

Joseph D Feuerstein (JD)

Division of Gastroenterology, Beth Israel Deaconess Medical Center Medicine, 330 Brookline Ave, Boston, MA, 02215, USA.
Harvard Medical School, Boston, MA, USA.

Liliana Grigorievna Bordeianou (LG)

Division of Gastrointestinal and Oncologic Surgery, Massachusetts General Hospital, 55 Fruit St, Boston, MA, 02114, USA.
Harvard Medical School, Boston, MA, USA.

Richard Hodin (R)

Division of Gastrointestinal and Oncologic Surgery, Massachusetts General Hospital, 55 Fruit St, Boston, MA, 02114, USA.
Harvard Medical School, Boston, MA, USA.

Hiroko Kunitake (H)

Harvard Medical School, Boston, MA, USA.
Advocate Illinois Masonic Medical Center, 836 W Wellington Ave, Chicago, IL, 60657, USA.

Vitaliy Poylin (V)

Division of Gastrointestinal and Oncologic Surgery, Northwestern Medicine, Arkes Family Pavilion, 676 North Saint Clair Street, Suite 650, Chicago, IL, 60611, USA. vitaliy.poylin2@nm.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH